FGEN Fibrogen Inc
Price (delayed)
$0.5188
Market cap
$52.28M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.23
Enterprise value
$52.91M
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue
Highlights
The company's EPS has surged by 60% YoY and by 28% QoQ
The net income has surged by 59% year-on-year and by 28% since the previous quarter
FGEN's equity has dropped by 55% year-on-year and by 4.9% since the previous quarter
The quick ratio has contracted by 38% YoY and by 15% from the previous quarter
Key stats
What are the main financial stats of FGEN
Market
Valuations
Earnings
Shares outstanding
100.77M
Market cap
$52.28M
Enterprise value
$52.91M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.29
Revenue
$180.01M
Gross profit
$138.38M
Operating income
-$112.96M
Net income
-$121.79M
EBIT
-$102.09M
EBITDA
-$97.87M
Free cash flow
-$125.39M
Per share
Balance sheet
Liquidity
EPS
-$1.23
EPS diluted
-$1.23
Free cash flow per share
-$1.25
Book value per share
-$2.43
Revenue per share
$1.79
TBVPS
$2.63
Total assets
$264.42M
Total liabilities
$466.12M
Debt
$131.63M
Equity
-$243.67M
Working capital
$54M
Debt to equity
-0.54
Current ratio
1.28
Quick ratio
0.84
Net debt/EBITDA
-0.01
Margins
Efficiency
Dividend
EBITDA margin
-54.4%
Gross margin
76.9%
Net margin
-67.7%
Operating margin
-62.7%
Return on assets
-36.2%
Return on equity
N/A
Return on invested capital
-48.6%
Return on capital employed
-138.2%
Return on sales
-56.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FGEN stock price
How has the Fibrogen stock price performed over time
Intraday
13.77%
1 week
3.76%
1 month
-11.9%
1 year
-76.09%
YTD
-2.02%
QTD
-2.02%
Financial performance
How have Fibrogen's revenue and profit performed over time
Revenue
$180.01M
Gross profit
$138.38M
Operating income
-$112.96M
Net income
-$121.79M
Gross margin
76.9%
Net margin
-67.7%
Fibrogen's operating margin has soared by 67% YoY and by 32% from the previous quarter
The company's net margin has surged by 64% YoY and by 30% QoQ
FGEN's operating income has surged by 62% year-on-year and by 29% since the previous quarter
The net income has surged by 59% year-on-year and by 28% since the previous quarter
Growth
What is Fibrogen's growth rate over time
Valuation
What is Fibrogen stock price valuation
P/E
N/A
P/B
N/A
P/S
0.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.29
The company's EPS has surged by 60% YoY and by 28% QoQ
FGEN's equity has dropped by 55% year-on-year and by 4.9% since the previous quarter
The stock's price to sales (P/S) is 97% less than its 5-year quarterly average of 9.7 and 64% less than its last 4 quarters average of 0.7
The company's revenue rose by 16% YoY and by 3.6% QoQ
Efficiency
How efficient is Fibrogen business performance
The company's return on sales has surged by 69% YoY and by 34% QoQ
FGEN's return on invested capital is up by 46% year-on-year and by 10% since the previous quarter
FGEN's return on assets is up by 35% year-on-year and by 17% since the previous quarter
Dividends
What is FGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FGEN.
Financial health
How did Fibrogen financials performed over time
FGEN's total assets is 43% smaller than its total liabilities
FGEN's total assets is down by 43% year-on-year and by 10% since the previous quarter
The quick ratio has contracted by 38% YoY and by 15% from the previous quarter
The company's debt is 154% higher than its equity
FGEN's debt to equity has soared by 58% YoY and by 37% from the previous quarter
FGEN's equity has dropped by 55% year-on-year and by 4.9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.